Human Follicle Stimulating Hormone (FSH)

Indications & Dose:

Women: it is used to treat the polycystic ovary and in assisted reproductive programs. Sequential administration of Follitrin® 75 and Human Chorionic Gonadotropin (HCG) are indicated to patients with polycystic ovary syndrome (PCO) with a high LH/FSH relation and who failed to respond to anappropriate treatment.

 DOSE

Adequated to each patient according to the therapeutic use andtype of response obtained. The inicial recommended daily dose is 75 I.U., and echographic controls and plasma and / or urinary hormonal determinationsshould be performed until the proper follicle maturation parameters are reached.

In women, one day after the last administration of 75, 5.000 to 10.000 I.U. of HCG should be injected. If ovaries appear to be abnormally enlarged on the last day of administration of 75, HCG should not be administered during that treatment. The recommended product regimen of administration should not exceed 12 continuous days within the same treatment period. If there is evidence of ovulation but pregnancy signs are absent, the dosage regimen should be repeated for at least two more cycles, then 75 administration should be increased to 150 I.U. per day for 7 to 12 days followed by the administration of 5.000 to 10.000 I.U. of HCG. If there is evidence of ovulation but pregnancy signs are absent, the dosage regimen should be repeated for at least two more treatment periods. During the 75 and HCG treatment, patients should be examined for two weeks followed the last administration to detect ovarian hyperstimulation signs. The administration of 75 should be discontinued if ovaries are abnormally enlarged or if abdominal pain is present.

Most cases of ovarian hyperstimulation syndrome take place following treatment discontinuation and finish around seven to ten days after ovulation. The couple should be advised to have daily sexual intercourse, starting the day before HCG administration and until ovulation takes place.

(Dissolve the content of the vial in 1 ml of 0.85% sodium chloride solution and administer intramuscularly / subcutaneously immediately. Any remaining reconstituted material should be discarded.)

Contraindications:

Early ovarian failure Gynecological hemorrhage of unknown etiology. Hypophysial tumors. Ovarian, uterine, and mammary carcinoma. Thyroid and adrenal dysfunction. Ovarian cyst or enlargement not caused by polycystic ovarian syndrome. Hypersensitivity to human follicle stimulating hormone. Pregnancy

Side Effects:

Cautions:

Precautions:

Cases of multiple pregnancies can take place during the ovulation induction treatments. It is advised not to administer HCG if ovarian hyperstimulation is suspected. 

Interaction:

Interactions with other drugs or foods are not known.

Carcinogenesis and mutagenesis: Related information is unknown.

Lactating mothers: It is not known if this drug is secreted into breast milk. 

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

 Ovarian hyperstimulation syndrome.
 Pulmonary and vascular complications.
 Hemoperitoneum
  Adnexal torsion.
 Mild to moderate ovarian enlargement.
 Ovarian cyst.
 Abdominal pain.
 Hypersensitivity to the drug.
 Gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal cramps).
 Pain, tetter, swelling, and / or irritation at the site of injection.
 Dizziness, tachycardia, dyspnea, accelerated breathing.
 Ectopic pregnancy

Patient And Carer Advice: